皮损内注射皮质类固醇治疗多发性暴发性角化棘皮瘤：病例报告及对一种有争议疗法的综述
Intralesional corticosteroid treatment of multiple eruptive keratoacanthomas: case report and review of a controversial therapy.
作者信息
Sanders Scott, Busam Klaus J, Halpern Allan C, Nehal Kishwer S
机构信息
Dermatology Service and Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
出版信息
Dermatol Surg. 2002 Oct;28(10):954-8. doi: 10.1046/j.1524-4725.2002.02069.x.
BACKGROUND
Use of intralesional corticosteroids in the management of keratoacanthomas has been reported in older literature. Yet this therapy is no longer a commonly considered treatment option.
OBJECTIVE
To report management of a therapeutically challenging patient with multiple eruptive keratoacanthomas with intralesional corticosteriod treatment to revive awareness of this treatment option.
METHODS
A 55-year-old female with frequent episodes of multiple eruptive keratoacanthomas was treated with intralesional corticosteroids and methotrexate.
RESULTS
Intralesional corticosteroids successfully treated eruptive keratoacanthomas with complete regression and minimal scarring within 2-4 weeks.
CONCLUSION
Despite its limitations, intralesional corticosteroids may have a role in the treatment of select keratoacanthomas.
背景
早期文献报道了病灶内注射皮质类固醇激素用于治疗角化棘皮瘤。然而，这种治疗方法已不再是常用的治疗选择。
目的
报告一名患有多发性暴发性角化棘皮瘤的具有治疗挑战性的患者，采用病灶内注射皮质类固醇激素治疗，以唤起对这种治疗选择的认识。
方法
一名55岁女性，频繁发作多发性暴发性角化棘皮瘤，接受病灶内注射皮质类固醇激素和甲氨蝶呤治疗。
结果
病灶内注射皮质类固醇激素成功治疗了暴发性角化棘皮瘤，在2 - 4周内完全消退，瘢痕形成最小。
结论
尽管有其局限性，但病灶内注射皮质类固醇激素可能在某些角化棘皮瘤的治疗中发挥作用。
Zotero 插件